Our press releases
-
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
-
uniQure Announces Pricing of its Public Offering (2018)
-
Curetis Announces Change of the Composition of Its Supervisory Board
-
Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance For 2018
-
Curetis to Publish its 2017 Annual Results on April 30, 2018
-
Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
-
Curetis: Novel Products and Study Data to be Presented at ECCMID 2018
-
Allecra Therapeutics to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases
-
Forbion participates in £29M Series B Financing of Enterprise Therapeutics to Advance its Ion Channel Modulators for the treatment of Cystic-fibrosis, COPD and severe asthma
-
Curetis Establishes U.S. Scientific Advisory Board
-
Curetis Receives U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge
-
Curetis’ Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority
-
Allecra Therapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
-
Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to Treat Complicated Urinary Tract Infections (cUTI)
-
Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018
-
Forbion’s Portfolio Company, Prexton Therapeutics Acquired by Lundbeck for up to EUR 905 million (USD 1.1 billion)
-
Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology
-
Forbion leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases
-
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
-
Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley
-
Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis
-
Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections
-
Curetis Group: Ares Genetics Receives Funding Commitment For EUR 1.6 Mio. Project; Curetis Announces Non-Audited Financial Results for 2017
-
Curetis Unyvero HPN Application Receives Singapore Health Sciences Authority Approval; Updates on Sepsis Host Response Test
-
Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology
-
Curetis Expects Near-Term FDA Decision on De Novo Request
-
Sanifit announces the appointment of Cris Calsada as Chief Financial Officer
-
Sanifit Announces Last Patient Last Visit completed in Clinical Trial of SNF472 in Patients with Calciphylaxis
-
uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
-
Forbion leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programme
-
uniQure Added to NASDAQ Biotechnology Index
-
Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing
-
uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
-
Allecra Therapeutics Announces New Staged Financing Deal to Take the Company Through to End of Phase 3
-
Curetis Publishes Business and Financial Update for the First Nine Months of 2017
-
enGene named Company of the Year by BIOTECanada
-
uniQure Announces Pricing of its Public Offering
-
Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge
-
uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
-
uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family
-
Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors
-
uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease
-
KaNDy Therapeutics launched to advance a breakthrough treatment in Women's Health
-
NeRRe Therapeutics appoints Andrew Kay as Chairman of the Board
-
MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics
-
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs
-
Allecra Announces Initiation of a Phase 2 Clinical Trial for its Novel Antibiotic to Treat Resistant Bacterial Infections
-
MSD to Acquire Rigontec
-
Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS
-
CareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic Tests
